Clinical Trial Update: A Study in Myeloproliferative Disorders [Phase 1]

View source ↗

Summary

Phase 1 study in myeloproliferative neoplasms has completed, evaluating patients with essential thrombocythemia, polycythemia vera, and primary myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Myeloproliferative Neoplasms
• Polycythemia Vera

Snippet

Sponsor: Eli Lilly and Company | Conditions: Myeloproliferative Disorders, Thrombocythemia, Essential | Phase 1 | Status: COMPLETED